{"name":"Bioiberica","slug":"bioiberica","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Droglican","genericName":"Droglican","slug":"droglican","indication":"Other","status":"marketed"},{"name":"Paracetamol or oral NSAIDs excluding COX2 inhibitors","genericName":"Paracetamol or oral NSAIDs excluding COX2 inhibitors","slug":"paracetamol-or-oral-nsaids-excluding-cox2-inhibitors","indication":"Other","status":"marketed"},{"name":"Tendoactive","genericName":"Tendoactive","slug":"tendoactive","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Droglican","genericName":"Droglican","slug":"droglican","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Paracetamol or oral NSAIDs excluding COX2 inhibitors","genericName":"Paracetamol or oral NSAIDs excluding COX2 inhibitors","slug":"paracetamol-or-oral-nsaids-excluding-cox2-inhibitors","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tendoactive","genericName":"Tendoactive","slug":"tendoactive","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxNVGxOekYtNVRGbjROMlVicU9CcF9mcHRBQzVBR21jQm5mc3hwNGJOWVVnZHg4ZFUtQTJyaGFHcGdKemxZLW00a0ZBVkpYZmZPaWdMdWRLM2hIWldmSnZtLXY3V1o0OUpLTTJ2djVEaDZxYm9WcWJ5SjJKUGFYM2JNYnoxOG5LMVFNaWVuQWFmcDA0ci1XSHVSN1h6ZWI3Y3E2dFBvdTUwZVp5aEFRWW1mZkZsQQ?oc=5","date":"2026-03-02","type":"pipeline","source":"Nutrition Insight","summary":"The Collagen Market Pulse report: what’s real and what’s next? - Nutrition Insight","headline":"The Collagen Market Pulse report: what’s real and what’s next?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQRkRzMzZJQTRMUXFPT0VBZ1F4cGd2dGVKZldRQnFhdHE0Z29ZVzZTVTR1UkJWcWs1aC10Y0JjVkpCWFk3Sm1YaGR2SjhaRWpaVXVfckIwWlVhS0o1T3U5aGEtNXRrR0JLV213YUlFWXFqS3lhRlpUc2tha3RTVHEzTFNzZHpjUG82MFcweWpWU3V4N3pvZ1dGV2cxYlZUYWs?oc=5","date":"2025-11-03","type":"pipeline","source":"Nutrition Insight","summary":"CPHI 2025: Redefining nutraceuticals with new delivery formats and pharma-grade standards - Nutrition Insight","headline":"CPHI 2025: Redefining nutraceuticals with new delivery formats and pharma-grade standards","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMia0FVX3lxTE92cDhrNDV4c1ZWaG5aWDZNclpjQmtWSEI0MXVLN3RIRjJ2TVBmaWJoQ0NEVS01SkxMakIya1ZZQkRnYmx0WDQyQmxXMWZXY3ppMEI4N2UtZ3ZiUnhoUmg1R0hrejhPYjgtLTg0?oc=5","date":"2025-09-17","type":"pipeline","source":"Market.us","summary":"Chondroitin Sulfate Market Size, Share | CAGR of 3.6% - Market.us","headline":"Chondroitin Sulfate Market Size, Share | CAGR of 3.6%","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxONjlpaVRHZHdFenNteE5XU29JaEFOVnFlYjQtSjZnSlRfMW1HWGE3VnpocExMVldTd0VmU3U1dXBXX2lyM3UwTmVvMmJfX002NEdNclNoc2FSTmJ5WjNlVFZocGNjLTRyTlhBZ2UxOXFuLUxENWYxWi1ERVZtZkJMQWNkem5UUEVIVzhUUVRsZHZWclNPUEVuSkpwRnBZdDlXX1pTYkNGbTZRSE1jVXBXcXM4U2xCOWNvY1Brcll4NA?oc=5","date":"2025-06-20","type":"pipeline","source":"Nutrition Insight","summary":"Bioiberica: Expanding from pharma to targeted nutraceuticals in 50-year history - Nutrition Insight","headline":"Bioiberica: Expanding from pharma to targeted nutraceuticals in 50-year history","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxORWpNcVR0NFBJRjlUSGFBSzdpQkx2UWlBa1F1dVFzb3ZjMTZkd1pMME0xR2F4cktINHFXQWhOdFJXci1fZUU0Y01Iek02TENKSnBsTXpweDcyNUplWUREODV6cWlvT0VFcDZaWkZUZzJqQ0MzdnJDSEs4aHJQVzVNcXZ6ZDVwRFQybGQ0?oc=5","date":"2024-02-23","type":"pipeline","source":"Nutraceutical Business Review","summary":"Bioiberica names Luis Solera new CEO - Nutraceutical Business Review","headline":"Bioiberica names Luis Solera new CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPM2sxS1BWUEhTdnoyX3k1Y0hsbHZiRUl0WDNLNjZtNEREN1cyMW9rd2RXZ1hyaGJmd1VoS1BFNmIzZjBFZjJrcmotRXRWaHB5VkVXQTVZYjNlRTJweDNIUXhqLVRlMEl1VHh6NllXeUxVNHhYckJOZ2hHNEhreS1fcC1fWWRBc0ZnQnFSNzlmdWJMSHNzQXlLY3QwWDh1emZCSVZ4My1xRE5YVERPMjFMUEFIME9TZm5wOXB6MmVTM2lJNzV5X3M5T205ZF8?oc=5","date":"2022-10-14","type":"pipeline","source":"Nutraceutical Business Review","summary":"Bioiberica to demonstrate complete pharma and nutra ingredient portfolio at CPHI 2022 - Nutraceutical Business Review","headline":"Bioiberica to demonstrate complete pharma and nutra ingredient portfolio at CPHI 2022","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPY1NQeEVCRFFGMGdOQXg4R1E4T1pzYmFucmZFZWthX2pvY2I3RTkxQktHTlNSWHRNc2pmbGpEbmVIYUxXUjNlN0tnUFkzTUZLMXRfUDFjUENlclB6Z1hsSUhOcV9fQVlPR09iOUl6d1hoY0ZTLU9HYWVJTXNFNFRUd1ZRMTZGVDdDaXN1cFZpMkVKNDNtNjdZOHBGUUFEa2htYkNBN1BzaW82R0J0eXl3QXZjRnZpdEhFX3pKSGRCbU82N3dC?oc=5","date":"2022-06-23","type":"regulatory","source":"Fierce Pharma","summary":"Mexico's Glinsa suffers warning letter and import alert after refusing FDA manufacturing inspection - Fierce Pharma","headline":"Mexico's Glinsa suffers warning letter and import alert after refusing FDA manufacturing inspection","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPMFp2NnVRcmtOQnZGd3hzOTMtV3RieTRnS3FJazRkVlRHeW1McFBFMWhUSko1TDIxMGZmWW1hNmxmeUtYbUJQRUsxQlBQSW93QUluaHhnaTF2R1NnQTdDZFI3dkVwMFllT3NLdDFrRm51RHBDU29jaGlLR2xlRDlxUm0xNVdoU3hpbFVGSEpzM1d4dTFoR2tOVXlLX2hDVE1Z?oc=5","date":"2022-06-16","type":"regulatory","source":"Fierce Pharma","summary":"FDA hits Spanish drug substance maker Bioiberica with a Form 483 - Fierce Pharma","headline":"FDA hits Spanish drug substance maker Bioiberica with a Form 483","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE1uRUxqa0c5UXRSQkJOLWpCLXVfZUQ2UEY5Q3I2WHBsZThtblVNaVJXdmJmN251QWJNZXdlcW5XZjN4YUVnalBPV0FWYktpZXBsMzNjMHZHdFI5YVdzX29zUlhfWjAzdVp4UVlCb0RRblc4X2JKV3c?oc=5","date":"2019-02-05","type":"pipeline","source":"Manufacturing Chemist","summary":"Bioiberica modernises brand - Manufacturing Chemist","headline":"Bioiberica modernises brand","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5sVURIbFBOQjlST1AzVnZEQjl0LUJvRkZJTThsdlNlZTNhUUVra2ltRVVjYmU1azBmVjdZdU5FNDdkRFlBamEwQTJjMHVCZEdtejdSdU9hMnlrZE51OGFFQnFnd0dKSEV0bXkxcV9EUGoxRUxsRnBEZEh3?oc=5","date":"2018-10-09","type":"pipeline","source":"Nutraceutical Business Review","summary":"New animal-derived APIs - Nutraceutical Business Review","headline":"New animal-derived APIs","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":2,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}